EU Regulatory Body Rejects Lecanemab, An Alzheimer’s Medicine
A licence for an Alzheimer’s medication that reduces cognitive decline has been denied by the European Medicines Agency (EMA). According to the EMA, lecanemab’s advantages did not outweigh the possibility of major adverse effects, such as brain swelling and haemorrhage. A decision about the granting of a licence is still pending from the UK’s pharmaceuticals…









